Streetbeat News

Analyst Ratings

RVMD

Barclays analyst Peter Lawson has maintained an Overweight rating on Revolution Medicines (NASDAQ:RVMD) and increased the price target from $54 to $60.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 6:08 pm

DT

Analysts have mixed ratings for Dynatrace (NYSE:DT), with recent evaluations showing a slight decrease in average price targets. The company's financials reveal strong revenue growth and net margins, but challenges in ROE and ROA. Analysts' ratings and price targets provide insights into market perceptions.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 6:06 pm

TVTX

Travere Therapeutics (NASDAQ:TVTX) has been analyzed by 14 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target increased by 11.37% to $19.79. Recent analyst actions include both raises and lowers in price targets, reflecting mixed sentiments. Travere's financials show a positive revenue trend but challenges in ROE and ROA, with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 6:05 pm

GM

Whales are showing a bullish stance on General Motors (GM) with significant options activity. 75% of the trades are bullish, focusing on a price range of $38 to $52.5. Despite this, analysts have mixed ratings, with some downgrading GM's stock. GM's stock is currently up 1.43% at $46.47.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 6:04 pm

MET

Jefferies analyst Suneet Kamath has maintained a Buy rating on MetLife and increased the price target from $89 to $95.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:58 pm

NDAQ

RBC Capital analyst Ashish Sabadra has initiated coverage on Nasdaq Inc (NDAQ) with an Outperform rating and a price target of $88, citing growth prospects following the Adenza acquisition. The analyst highlights Nasdaq's strong position in the market, driven by secular trends and a robust solutions revenue growth forecast.

Portfolio Pulse from Anusuya Lahiri

September 27, 2024 | 5:52 pm

BMEA

HC Wainwright & Co. has maintained a Buy rating on Biomea Fusion and raised the price target from $15 to $40, indicating strong confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:38 pm

JCI

B of A Securities analyst Andrew Obin maintains a Buy rating on Johnson Controls Intl (NYSE:JCI) and raises the price target from $80 to $95.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:37 pm

DT

Guggenheim analyst John Difucci has maintained a Buy rating on Dynatrace (NYSE:DT) and increased the price target from $55 to $64.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 5:35 pm

TMUS

Unusual options activity has been detected for T-Mobile US (NASDAQ:TMUS), with a significant amount of bearish sentiment among large investors. Despite this, analysts maintain positive ratings and high price targets for the stock.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 5:35 pm